Cardiovascular, Renal and Metabolic Disease (CVMD)Our mission is to save patients’ lives by jointly addressing their cardio-renal-metabolic risks.

More than 415 million adults worldwide have diabetes, with up to 642 million expected by 20405

More than 17.5 million people worldwide die from CVD every year1

An estimated 200 million people worldwide have CKD4

With this knowledge, we are daring to do things differently by shifting focus from treating patients with a single disease, to addressing overlapping disease areas and risk factors.

Metabolic

Cardio

RenalCVD is the leading cause of death in people with CKD and people with diabetes5,7

Hyperkalaemia occurs in up to 50% of patients with CKD and approximately 20% of patients with chronic heart failure (HF) taking mineralocorticoid receptor antagonists8,9

Overlapping disease statesThe growing unmet need in CVMD

Our distinctive approach to CVMD

Science is uncovering commonalities between CV, renal and metabolic disease, explaining why the idea of reducing CV risk is so complex.

Despite scientific advancements, cardiovascular disease (CVD) can cause high residual risk for recurrent cardiac events in certain patients and remains the #1 cause of death globally.1,2

From 2011 to 2025, the cumulative economic losses in low-income and middle-income countries from CVD are projected to be US $3.76 trillion3

Type-2 diabetes is one of the top causes of CKD5

Strategic Partnerships Rigorous Clinical Studies

Reference | 1. World Health Organization. Cardiovascular Disease Fact Sheet. Accessed 27 June 2017. http://www.who.int/mediacentre/factsheets/fs317/en/. 2. Joshi PH, Martin SS, et al. The Remnants of Residual Risk. J Am Coll Cardiol. 2015; 65(21): 2276-2278 3. Laslett L, et al. “The Worldwide Environment of Cardiovascular Disease: Prevalence, Diagnosis, Therapy, and Policy Issues: A Report From the American College of Cardiology.” J Am Coll Cardiol. 2012; 60 (25): S1-S49. 4. Ojo A. Addressing the Global Burden of Chronic Kidney Disease Through Clinical and Translational Research. Transactions of the American Clinical and Climatological Association. 2014; 125: 229-246. 5. International Diabetes Federation. IDF Diabetes Atlas, 7th ed. Brussels, Belgium: International Diabetes Federation, 2015. 6. LoCasale RJ, Gannedahl G, Wang J, et al. Describing the cardio-renal-metabolic patient within the Diabetes Collaborative Registry. Poster presented at the American Diabetes Association 77th Scientific Sessions, 9-13 June 2017, San Diego, CA, USA.

Veeva Z4-6033 | Date of preparation: August 2017 | Date of expiry: August 2018

7. National Institutes of Health. "Chronic Kidney Disease and Kidney Failure." Accessed 27 June 2017. https://report.nih.gov/nihfactsheets/ViewFactSheet.aspx?csid=34. 8. The RALES Investigators. Effectiveness of Spironolactone Added to an Angiotensin-Converting Enzyme Inhibitor and a Loop Diuretic for Severe Chronic Congestive Heart Failure (The Randomized Aldactone Evaluation Study [RALES]). J Am Coll Cardiol. 1996; 78(8):902-907. 9. The National Kidney Foundation. Clinical Update on Hyperkalaemia. 2014. https://www.kidney.org/sites/default/files/02-10-6785_HBE_Hyperkalemia_Bulletin.pdf. Accessed 27 June 2017.

For medical media use

We are committed to delivering life-changing results for people living with CVMD,with medicines that have the potential to offer improved outcomes to hundreds of millions of patients across the globe.

We continue to strengthen our commitment to following the science through:

therapies and therapy combinations in our early to late-stage pipeline

60,000+ patients participating in Research & Development-led CV trials at 6,000+ sites worldwide

We are evaluating the use of our medicines in large patient populations in both established and emerging markets. These trials include ambitious global randomised clinical trials that are as close as possible to clinical practice, as well as transformational real-world evidence research